Nothing but NET: A Review of Norepinephrine Transporter Expression and Efficacy of 131I-mIBG Therapy

被引：55

作者：

Streby, Keri A. ^{[1
,2
]}

Shah, Nilay ^{[1
,2
]}

Ranalli, Mark A. ^{[1
,2
]}

Kunkler, Anne ^{[2
]}

Cripe, Timothy P. ^{[1
,2
]}

机构：

[1] Ohio State Univ, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH 43210 USA

[2] Ohio State Univ, Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Columbus, OH 43210 USA

来源：

PEDIATRIC BLOOD & CANCER | 2015年 / 62卷 / 01期

关键词：

meta-iodobenzylguanidine; neuroblastoma; norepinephrine transporter; SK-N-SH; HUMAN NEUROBLASTOMA-CELLS; POLYMERASE-CHAIN-REACTION; RADIATION-INDUCED BYSTANDER; I DOSE-ESCALATION; REFRACTORY NEUROBLASTOMA; NORADRENALINE TRANSPORTER; METAIODOBENZYLGUANIDINE UPTAKE; TARGETED RADIOTHERAPY; PHASE-I;

D O I：

10.1002/pbc.25200

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for I-123-metaiodobenzaguanidine (mIBG) on imaging, yet the therapeutic response to I-131-mIBG is only 30% in clinical trials, and off-target effects cause short- and long-term morbidity. We review the contemporary understanding of the tumor-selective uptake, retention, and efflux of meta-iodobenzylguanidine (mIBG) and strategies currently in development for improving its efficacy. Combination treatment strategies aimed at enhancing NET are likely necessary to reach the full potential of I-131-mIBG therapy. Pediatr Blood Cancer 2015;62:5-11 (c) 2014 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.

引用

页码：5 / 11

页数：7

共 103 条

[1]

Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733

[2] MODIFICATION OF METAIODOBENZYLGUANIDINE UPTAKE IN NEUROBLASTOMA-CELLS BY ELEVATED-TEMPERATURE [J].

ARMOUR, A ;

MAIRS, RJ ;

GAZE, MN ;

WHELDON, TE .

BRITISH JOURNAL OF CANCER, 1994, 70 (03) :445-448

[3] The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro [J].

Armour, A ;

Cunningham, SH ;

Gaze, MN ;

Wheldon, TE ;

Mairs, RJ .

BRITISH JOURNAL OF CANCER, 1997, 75 (04) :470-476

[4] Comparison of High-Specific-Activity Ultratrace 123/131I-MIBG and Carrier-Added 123/131I-MIBG on Efficacy, Pharmacokinetics, and Tissue Distribution [J].

Barrett, John A. ;

Joyal, John L. ;

Hillier, Shawn M. ;

Maresca, Kevin P. ;

Femia, Frank J. ;

Kronauge, James F. ;

Boyd, Marie ;

Mairs, Robert J. ;

Babich, John W. .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2010, 25 (03) :299-308

[5]

Bishayee A, 2000, RADIAT RES, V153, P416, DOI 10.1667/0033-7587(2000)153[0416:PBDACD]2.0.CO

[6]

[7] Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis [J].

Bleeker, Gitta ;

Schoot, Reineke A. ;

Caron, Huib N. ;

de Kraker, Jan ;

Hoefnagel, Cees A. ;

van Eck, Berthe L. ;

Tytgat, Godelieve A. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (11) :1711-1717

[8]

Bönisch H, 2006, HANDB EXP PHARM, V175, P485

[9] THE NORADRENALINE TRANSPORTER OF THE NEURONAL PLASMA-MEMBRANE [J].

BONISCH, H ;

BRUSS, M .

MOLECULAR AND CELL BIOLOGICAL ASPECTS OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE, 1994, 733 :193-202

[10] Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill [J].

Boyd, M ;

Mairs, RJ ;

Mairs, SC ;

Wilson, L ;

Livingstone, A ;

Cunningham, SH ;

Brown, MM ;

Quigg, M ;

Keith, WN .

ONCOGENE, 2001, 20 (53) :7804-7808

← 1 2 3 4 5 6 7 8 9 10 →